Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...
A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...
For more details about SABCS please visit: https://www.sabcs.org/.
Rakovina Therapeutics Inc., a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, has announced impressive results from its AI-enabled ATR program at the recent ...
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its ...
Psoriasis, a chronic inflammatory skin disease, relies heavily on abnormal angiogenesis for its pathogenesis, and AlkB ...
Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in ...
Komal Jhaveri - Breast Medical Oncologist and Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center, New York, ...
Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a ...
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback